Cargando…

Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report

Liposarcoma (LPS) is the most common soft tissue sarcoma. Myxoid LPS (MLPS) is the second most common subtype of LPS and accounts for 25% to 50% of all LPSs. Like most other soft tissue sarcomas, the mainstay of treatment for LPS is inevitably surgery. Multidisciplinary approaches, including surgery...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaojun, Zhang, Yanshan, Ye, Yancheng, Qi, Ying, Feng, Chunlan, Zhang, Yihe, Hu, Tingchao, Chen, Weizuo, Pan, Xin, Chai, Hongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074479/
https://www.ncbi.nlm.nih.gov/pubmed/33884917
http://dx.doi.org/10.1177/03000605211009701
_version_ 1783684361432858624
author Li, Xiaojun
Zhang, Yanshan
Ye, Yancheng
Qi, Ying
Feng, Chunlan
Zhang, Yihe
Hu, Tingchao
Chen, Weizuo
Pan, Xin
Chai, Hongyu
author_facet Li, Xiaojun
Zhang, Yanshan
Ye, Yancheng
Qi, Ying
Feng, Chunlan
Zhang, Yihe
Hu, Tingchao
Chen, Weizuo
Pan, Xin
Chai, Hongyu
author_sort Li, Xiaojun
collection PubMed
description Liposarcoma (LPS) is the most common soft tissue sarcoma. Myxoid LPS (MLPS) is the second most common subtype of LPS and accounts for 25% to 50% of all LPSs. Like most other soft tissue sarcomas, the mainstay of treatment for LPS is inevitably surgery. Multidisciplinary approaches, including surgery, chemotherapy, and radiotherapy, have been successful in the treatment of LPS during the last three decades. Even so, recurrence of LPS remains challenging. Carbon ion beams produce increased energy deposition at the end of their range to form a Bragg peak while minimizing irradiation damage to surrounding tissues, which facilitates more precise dosage and localization than that achieved with photon beams. Furthermore, carbon ion beams have high relative biologic effectiveness. We herein describe a patient who developed recurrent MLPS in the right calf after two surgeries and underwent carbon ion radiotherapy (CIRT), achieving complete disappearance of the tumor. The patient developed Grade 1 radiation dermatitis 30 days after CIRT, but no other acute toxicities were observed. The tumor had completely disappeared by 120 days after CIRT, and the patient remained disease-free for 27 months after CIRT. The CARE guidelines were followed in the reporting of this case.
format Online
Article
Text
id pubmed-8074479
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-80744792021-05-13 Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report Li, Xiaojun Zhang, Yanshan Ye, Yancheng Qi, Ying Feng, Chunlan Zhang, Yihe Hu, Tingchao Chen, Weizuo Pan, Xin Chai, Hongyu J Int Med Res Case Reports Liposarcoma (LPS) is the most common soft tissue sarcoma. Myxoid LPS (MLPS) is the second most common subtype of LPS and accounts for 25% to 50% of all LPSs. Like most other soft tissue sarcomas, the mainstay of treatment for LPS is inevitably surgery. Multidisciplinary approaches, including surgery, chemotherapy, and radiotherapy, have been successful in the treatment of LPS during the last three decades. Even so, recurrence of LPS remains challenging. Carbon ion beams produce increased energy deposition at the end of their range to form a Bragg peak while minimizing irradiation damage to surrounding tissues, which facilitates more precise dosage and localization than that achieved with photon beams. Furthermore, carbon ion beams have high relative biologic effectiveness. We herein describe a patient who developed recurrent MLPS in the right calf after two surgeries and underwent carbon ion radiotherapy (CIRT), achieving complete disappearance of the tumor. The patient developed Grade 1 radiation dermatitis 30 days after CIRT, but no other acute toxicities were observed. The tumor had completely disappeared by 120 days after CIRT, and the patient remained disease-free for 27 months after CIRT. The CARE guidelines were followed in the reporting of this case. SAGE Publications 2021-04-22 /pmc/articles/PMC8074479/ /pubmed/33884917 http://dx.doi.org/10.1177/03000605211009701 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Reports
Li, Xiaojun
Zhang, Yanshan
Ye, Yancheng
Qi, Ying
Feng, Chunlan
Zhang, Yihe
Hu, Tingchao
Chen, Weizuo
Pan, Xin
Chai, Hongyu
Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report
title Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report
title_full Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report
title_fullStr Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report
title_full_unstemmed Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report
title_short Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report
title_sort carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074479/
https://www.ncbi.nlm.nih.gov/pubmed/33884917
http://dx.doi.org/10.1177/03000605211009701
work_keys_str_mv AT lixiaojun carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT zhangyanshan carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT yeyancheng carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT qiying carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT fengchunlan carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT zhangyihe carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT hutingchao carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT chenweizuo carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT panxin carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport
AT chaihongyu carbonionradiotherapyforrecurrentcalfmyxoidliposarcomaacasereport